Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial by Christa Kasang (345821)

“…Secondary endpoints: Prednisolone-treatment decreased immune activation (sCD14, suPAR, CD38/HLA-DR/CD8+) and increased CD4-counts (+77.42 ± 5.70 cells/μl compared to -37.42 ± 10.77 cells/μl under placebo, p < 0.0001). …”

Summary of trend results based on Mann-Kendall test and Sen’s slope estimator for the 34 weather stations (arranged according to administrative division, in bold) for the wet seaso... by Mohammed Mainuddin (8723352)

Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes by Shiliang Li (298790)

“…The long-term antidiabetic efficacies of <b>5</b> (10 mg/kg, qw) were better than those of the once-weekly trelagliptin and omarigliptin, especially in decreasing the hemoglobin A1c level.…”

Gene Ontology network analysis of differentially-enriched Vpu-proximal protein subsets. by Charlotte A. Stoneham (10819125)

Uncertainty analyses of unadjusted data from Scenarios 1–3: each dot represents one simulation. by Jie Lou (535356)

Heat map and k-means clustering of proteins (384) for which any Vpu-mutant was significantly different from wild type. by Charlotte A. Stoneham (10819125)

Pair-wise comparison of the proximity-ome of wild type Vpu relative to the transmembrane domain mutant AAA/F. by Charlotte A. Stoneham (10819125)

IC₅₀ values of REJO SP mutants vs. WT by MAbs targeting V2i, V3, V2q, and the CD4bs and by CD-IgG2. by Chitra Upadhyay (817121)

Juxtanuclear endosomal distortion in cells expressing Vpu-S52,56N-APEX2. by Charlotte A. Stoneham (10819125)

Vpu-APEX2 fusion protein design and activity. by Charlotte A. Stoneham (10819125)

Longitudinal associations between baseline CVR and 2 years changes in BDI-II score in participants with a BDI-II score <18 in the PREDIMED-PLUS trial at baseline. by Sandra Martín-Peláez (11353470)

Association between cardiovascular risk and a) depressive status (BDI-II ≥18) and b) BDI-II score, in the PREDIMED-PLUS trial, stratified by CVR factors, at baseline. by Sandra Martín-Peláez (11353470)

Table_5_New evidence for the effect of type 2 diabetes and glycemic traits on testosterone levels: a two-sample Mendelian randomization study.xlsx by Chengyang Jiang (1540369)

Scheme [37] and photo of a device for extracting tritium from plants’ tissue free water (1 –organic glass container; 2 –lid; 3 –cone-shaped refrigerator; 4 –receiving tank holder;... by Yelena Polivkina (14341291)

Syntheses of Pentanuclear Group 6 Iridium Clusters by Core Expansion of Tetranuclear Clusters with Ir(CO)₂(η⁵‑C₅Me₄R) (R = H, Me) by Michael D. Randles (1902586)

“…Single-crystal X-ray diffraction studies of <b>1a</b>–<b>1d</b>, <b>2</b>, <b>3a</b>–<b>3d</b>, and <b>4</b> confirmed their molecular structures, including the μ-η¹:η⁵-CH₂C₅Me₄ ligand at hydrido cluster <b>2</b>, derived from a C–H bond activation of one of the methyl groups. …”

Inflammatory phenotype of APN-/- mice from a second strain. by Sri Harshini Goli (20889928)

Data_Sheet_1_Host Factor Nucleoporin 93 Is Involved in the Nuclear Export of Influenza Virus RNA.DOCX by Yuri Furusawa (5546819)

“…NUP93 knockdown mediated by siRNAs reduced viral replication and decreased the efficiency of the early step of the viral life cycle. …”

<i>Prss21</i>^<i>-/-</i> mice display a hemorrhagic phenotype during vascularization of the corpus luteum. by Raymond J. Peroutka (8946971)

PM26, a specific antagonist of DC-SIGN, can inhibit DC-SIGN/S protein interaction and trans-infection of VSV/SARS-CoV-2. by Michel Thépaut (7462022)

“…The IC₅₀ value for PM26 was estimated using GraphPad Prism v8 with a 95% confidence interval and settings for normalize dose-response curves (IC₅₀ = 94 nM, 95%CI = 35 nM– 249 nM).…”

Image_5_A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice.tif by Charlotte Chêne (11221620)

“…In vivo, in a cGvHD mouse model, daily injections of ATO 2.5 µg/g + CuCl₂ 0.5 µg/g induce a decrease in lymphocyte activation and fibrosis that was equivalent to that induced by ATO 5 µg/g. …”